In addition, YTHDF1, which is upregulated in prostate cancer samples, promotes PD-L1 expression in an m6A-PD-L1 manner, reduces effector T-cell toxicity and CD8 + T-cell-mediated immunosuppression and ferroptosis, and finally leads to poor clinical outcomes [99]. Here, CD274 is linked to prostate cancer.